Brief: Black Diamond Therapeutics -First Patients Dosed In Phase 1 Clinical Trial Expansion Cohorts Evaluating Bdtx-1535
11/09/2023 13:36
Sept 11 (Reuters) - Black Diamond Therapeutics Inc
BDTX.O :
* BLACK DIAMOND THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED
IN
PHASE 1 CLINICAL TRIAL EXPANSION COHORTS EVALUATING BDTX-1535 IN
PATIENTS WITH INTRINSIC DRIVER AND ACQUIRED RESISTANCE EGFR
MUTATION POSITIVE NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nGNX3X0hhB
Further company coverage: BDTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Black Diamond Therapeutics
See all newsBlack Diamond Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Black Diamond Therapeutics Q2 net loss narrows year over year
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Black Diamond Therapeutics Q4 net loss narrows, full-year profit turns positive
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox